Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk2256294. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 known ✓ | P34913 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk2256294 SCHEMBL2677671 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL2677673 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL2677667 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL29667411 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL30216212 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677883 | 0.89 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677886 | 0.89 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677878 | 0.89 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678417 | 0.88 | EPHX2 (0.79) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2676508 | 0.88 | EPHX2 (0.79) | EPHX2CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | claimed |
| WO-2024105225-A1 | SYNERGISTIC COMBINATIONS OF A SIGMA RECEPTOR 1 (S1R) ANTAGONIST AND A SOLUBLE EPOXIDE HYDROLASE INHIBITOR (SEHI) AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | claimed |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-03-14 | — | — | US | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | ASTRIZI BIO, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4665737-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| CN-115087659-A | Antiviral compounds | 吉利德科学公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220289737-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11426385-B2 | Methods of improving cancer chemotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022178215-A1 | AMINO AMIDE TETRAHYDRO IMIDAZO PYRIDINES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-110461839-B | JAK inhibitors containing 4-membered heterocyclic amides | 施万生物制药研发IP有限责任公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220218667-A1 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS OF USE THEREOF | OROX BIOSCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| CN-110382498-B | Fused imidazole-piperidine JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, ALDH1A2, EPHX2 | EPHX2 3/4885CYP2C9 3672/4885CYP3A4 3461/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | EPHX2 3400/4885CYP2C9 1733/4885CYP3A4 155/4885 |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | GLP1R, GIPR, GPR119 | EPHX2 3283/4885CYP2C9 2341/4885CYP3A4 2493/4885 |
| US-20220289737-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS | JAK2, JAK1, JAK3 | EPHX2 3237/4885CYP2C9 1268/4885CYP3A4 1555/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885CYP2C9 1964/4885CYP3A4 1578/4885 |
| US-11426385-B2 | Methods of improving cancer chemotherapy | ALOX5, EPHX1, ALOX12 | EPHX2 10/4885CYP2C9 213/4885CYP3A4 373/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | EPHX2 1139/4885CYP2C9 949/4885CYP3A4 1119/4885 |
| US-20220218667-A1 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS OF USE THEREOF | PTGES2, PTGS2, PTGES3 | EPHX2 4/4885CYP2C9 1732/4885CYP3A4 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.